Login to Your Account

Clinic Roundup

Wednesday, December 26, 2012
• OncoMed Pharmaceuticals Inc., of Redwood City, Calif., began dosing in a Phase I trial with OMP-52M51 in patients with hematologic cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription